Molnupiravir: New Drug Being Tested May Prevent Unvaccinated People from Getting COVID-19

The spike protein (red) mediates the coronavirus entry into host cells. It binds to the angiotensin converting enzyme 2 (blue) through its S1 subunit and then fuses viral and host membranes through the S2 subunits.
Lazy eyes listen

by Elisha Sauers, The Virginian-Pilot 

A Hampton Roads medical practice will recruit a handful of patients for a clinical trial to study a new drug that could stop people from contracting the coronavirus from others in their homes.

The trial aims to protect people who share a household with someone known to have tested positive for COVID-19. Only completely unvaccinated adults are eligible.

Tidewater Physicians Multispecialty Group is one of dozens of locations around the world collecting data for the study of molnupiravir, a new drug developed by Merck and Ridgeback Biotherapeutics.

For COVID-19, the federal government already has approved one antiviral drug — remdesivir — and authorized the use of three antibody therapies that help the immune system kick the virus. But all the drugs have to be given intravenously at hospitals or health care facilities.

Read full:

One minor detail…  Probably nothing…  It might be MUTAGENIC!

“In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties.[3] A previous company, Pharmasset, that had investigated the drug’s active ingredient had abandoned it.”